First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium

Julie Côté; Rami Kotb; Debra J Bergstrom; Richard LeBlanc; Hira S Mian; Ibraheem Othman; Martha L Louzada

doi:10.1016/j.clml.2023.01.016

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium

Clin Lymphoma Myeloma Leuk. 2023 May;23(5):340-354. doi: 10.1016/j.clml.2023.01.016. Epub 2023 Feb 3.

Authors

Julie Côté¹, Rami Kotb², Debra J Bergstrom³, Richard LeBlanc⁴, Hira S Mian⁵, Ibraheem Othman⁶, Martha L Louzada⁷

Affiliations

¹ Centre hospitalier universitaire de Québec, Quebec, QC, Canada. Electronic address: julie.cote.33@ulaval.ca.
² CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
³ Memorial University of Newfoundland St. John's, NL, Canada.
⁴ Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada.
⁵ Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁶ Allan Blair Cancer Centre, University of Saskatchewan, Regina, SK, Canada.
⁷ London Health Sciences Centre, Western University, London, ON, Canada.

PMID: 36925389
DOI: 10.1016/j.clml.2023.01.016

Abstract

Although the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM population may be limited by functional/frailty status. The Canadian Myeloma Research Group Consensus Guideline Consortium proposes consensus recommendations for the first-line treatment of transplant ineligible MM. To address the needs of physicians and people diagnosed with MM, this document further focuses on eligibility for transplant, frailty assessment, management of adverse events, assessment of treatment response, and monitoring for disease relapse. The Canadian Myeloma Research Group Consensus Guideline Consortium will periodically review the recommendations herein and update as necessary.

Keywords: Adverse events; Frailty assessment; Guidelines; Response and relapse monitoring; TIMM; Upfront treatment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Canada
Frailty*
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / therapy
Neoplasm Recurrence, Local
Quality of Life